215 related articles for article (PubMed ID: 32596745)
1. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.
Harrell MB; Ho K; Te AE; Kaplan SA; Chughtai B
World J Urol; 2021 Apr; 39(4):1233-1239. PubMed ID: 32596745
[TBL] [Abstract][Full Text] [Related]
2. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome.
Baas WR; Butcher MJ; Lwin A; Holland B; Herberts M; Clemons J; Delfino K; Althof S; Kohler TS; McVary KT
Urology; 2018 Oct; 120():143-149. PubMed ID: 29960004
[TBL] [Abstract][Full Text] [Related]
3. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
[TBL] [Abstract][Full Text] [Related]
4. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
[TBL] [Abstract][Full Text] [Related]
5. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
Pirozzi Farina F; Pischedda A
Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
[TBL] [Abstract][Full Text] [Related]
6. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
Fertig RM; Gamret AC; Darwin E; Gaudi S
Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628
[TBL] [Abstract][Full Text] [Related]
7. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System.
Gupta AK; Carviel J; Gupta MA; Shear NH
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1373-1376. PubMed ID: 29194783
[TBL] [Abstract][Full Text] [Related]
8. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
[TBL] [Abstract][Full Text] [Related]
9. Risk of rhabdomyolysis from 5-α reductase inhibitors.
Welk B; McArthur E; Ordon M; Dirk J; Dixon S; Garg AX
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):351-355. PubMed ID: 29368380
[TBL] [Abstract][Full Text] [Related]
10. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
[TBL] [Abstract][Full Text] [Related]
11. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
[TBL] [Abstract][Full Text] [Related]
12. Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
Gupta MA; Vujcic B; Gupta AK
Skinmed; 2020; 18(3):146-150. PubMed ID: 32790610
[TBL] [Abstract][Full Text] [Related]
13. 5-alpha reductase inhibitors and erectile dysfunction: the connection.
Erdemir F; Harbin A; Hellstrom WJ
J Sex Med; 2008 Dec; 5(12):2917-24. PubMed ID: 19090946
[TBL] [Abstract][Full Text] [Related]
14. Atypical post-finasteride syndrome: A pharmacological riddle.
Gupta AK; Sharma N; Shukla P
Indian J Pharmacol; 2016; 48(3):316-7. PubMed ID: 27298504
[TBL] [Abstract][Full Text] [Related]
15. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
Arias-Santiago S; Camacho-Martínez FM
Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
[No Abstract] [Full Text] [Related]
16. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Lee S; Lee YB; Choe SJ; Lee WS
Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
[TBL] [Abstract][Full Text] [Related]
17. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
[TBL] [Abstract][Full Text] [Related]
18. The Cardiovascular Safety of Dutasteride.
Skeldon SC; Macdonald EM; Law MR; Huang A; Paterson JM; Mamdani MM; Juurlink D
J Urol; 2017 May; 197(5):1309-1314. PubMed ID: 27866006
[TBL] [Abstract][Full Text] [Related]
19. Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer.
Figg WD; Thompson IM
JAMA Oncol; 2015 Jun; 1(3):321-2. PubMed ID: 26181178
[No Abstract] [Full Text] [Related]
20. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
